-
NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)
(PAR-19-319)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): October 31, 2019; March 3, 2020; June 30, 2020, October 27, 2020; March 2, 2021; June 29, 2021; October 26, 2021; March 1, 2022; June 28, 2022 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)
(PAR-19-320)
National Institute of Nursing Research
Application Receipt Date(s): Standard dates apply
The first standard due date for this FOA is October 16, 2019.
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)
(PAR-19-321)
National Institute of Nursing Research
Application Receipt Date(s): Standard dates apply
The first standard due date for this FOA is October 5, 2019
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
(PAR-19-325)
National Cancer Institute
Application Receipt Date(s): September 30, 2019; February 11, 2020; September 30, 2020; February 11, 2021; September 20, 2021; February 11, 2022
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional)
(PAR-19-326)
John E. Fogarty International Center
National Cancer Institute
National Institute on Drug Abuse
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below
-
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
(PAR-19-327)
National Institute on Drug Abuse
Application Receipt Date(s): Applications will be accepted on a rolling basis, beginning on August 26, 2019.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date Applications are due by5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
-
Building Resources for the Basic Biology of Aging in Health Disparities Research (R24 Clinical Trial Not Allowed)
(RFA-AG-20-035)
National Institute on Aging
National Institute on Minority Health and Health Disparities
Application Receipt Date(s): October 18, 2019 and October 19, 2020
No late applications will be accepted for this Funding Opportunity Announcement.
-
Participant Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional)
(RFA-CA-19-045)
National Cancer Institute
Application Receipt Date(s): October 30, 2019; October 30, 2020
All applicants are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
No late applications will be accepted for this Funding Opportunity Announcement.
-
Participant Engagement and Cancer Genome Sequencing (PE-CGS): Coordinating Center (U24 Clinical Trial Not Allowed)
(RFA-CA-19-046)
National Cancer Institute
Application Receipt Date(s): October 30, 2019; July 30, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
No late applications will be accepted for this Funding Opportunity Announcement
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)
(RFA-CA-19-061)
National Cancer Institute
Application Receipt Date(s): November 20, 2019
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)
(RFA-CA-19-062)
National Cancer Institute
Application Receipt Date(s): November 20, 2019
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trials Optional)
(RFA-CA-19-063)
National Cancer Institute
Application Receipt Date(s): November 20, 2019
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Catalyst Award In Diabetes, Endocrinology and Metabolic Diseases (DP1 Clinical Trial Not Allowed)
(RFA-DK-19-014)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): December 3, 2019 by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on the listed date.
-
Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)
(RFA-ES-19-011)
National Institute of Environmental Health Sciences
Application Receipt Date(s): November 1, 2019; December 2, 2019; January 2, 2020; February 3, 2020; March 2, 2020; April 1, 2020; May 1, 2020; June 1, 2020; July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; February 1, 2021; March 1, 2021; April 1, 2021; May 3, 2021; June 1, 2021; July 1, 2021; August 2, 2021; September 1, 2021; October 1, 2021; November 1, 2021; December 1, 2021; January 3, 2022; February 1, 2022; March 1, 2022; April 1, 2022; May 2, 2022; June 1, 2022; July 1, 2022; August 1, 2022; September 1, 2022; October 3, 2022, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement.
-
US Children with Perinatal HIV who were Born Internationally (R01 Clinical Trial Optional)
(RFA-HD-20-006)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): November 14, 2019
-
The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R21 Clinical Trial Optional)
(RFA-HD-20-007)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): November 7, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.